Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

Key clinical trials at ESMO 2019

Key clinical trials at ESMO 2019

IMpower110

The IMpower110 researchers will report OS data from the comparison of first-line atezolizumab with chemotherapy in PD-L1-selected NSCLC patients.

Friday, September 27

RADICALS

Results from the radiotherapy timing comparison of this multi-arm trial comprising men who have undergone surgery for nonmetastatic prostate cancer will be reported.

Friday, September 27

Checkmate 227

CheckMate 227 is a multi-part trial evaluating the efficacy of nivolumab – either alone or in various combinations – in patients who have not received prior therapy for advanced NSCLC.

Saturday, September 28

FLAURA

This phase III trial has previously shown significant gains in PFS with first-line osimertinib for EGFR-mutated NSCLC. Delegates at ESMO 2019 will find out whether this translates into an OS benefit.

Saturday, September 28

ENTRATA

ENTRATA is investigating the addition of the novel glutaminase inhibitor telaglenastat to everolimus in heavily pretreated patients with advanced RCC.

Saturday, September 28

TROPHY-U-01

This is a trial of the antibody–drug conjugate sacituzumab govitecan as second- or third-line therapy for metastatic urothelial cancer patients.

Saturday, September 28

CASPIAN

More data from the CASPIAN trial of durvalumab–etoposide in extensive-stage SCLC will be presented, following the initial positive findings.

Saturday, September 28

PROfound

The PROfound study aims to establish a role for the PARP inhibitor olaparib in men with metastatic CRPC positive for homologous recombination repair gene mutations.

Monday, September 30

CARD

The CARD study is testing whether patients with metastatic CRPC who progress rapidly during antiandrogen treatment fare better with cabazitaxel or an alternative antiandrogen.

Monday, September 30

IMvigor130

IMvigor130 is assessing immunotherapy with atezolizumab – either as monotherapy or in combination with chemotherapy – in the advanced urothelial carcinoma setting.

Monday, September 30

PROMISE-meso

Is pembrolizumab more efficacious than chemotherapy for previously treated malignant pleural mesothelioma? The PROMISE-meso investigators aim to find out.

Monday, September 30

B-FAST

The B-FAST trial is using blood-based assays to identify actionable molecular markers in patients with advanced NSCLC. Results from the ALK-positive cohort will be reported.

Monday, September 30